• Canada’s Inversago raises $7M to target cannabinoid receptors fiercepharma
    July 30, 2018
    Inversago Pharma reeled in a $7 million series A round to move a suite of next-generation cannabinoid receptor-1 (CB1) blockers into the clinic. The Montreal-based startup is developing the drugs for Prader-Willi syndrome, as well as metabolic disorders i
PharmaSources Customer Service